600709-74-8

Basic information

• Product Name: N-[1-(4-hydroxy)butyl]indole-2-carboxamide
• Synonyms: N-[1-(4-hydroxy)butyl]indole-2-carboxamide
• CAS NO: 600709-74-8
• Molecular Formula: C₁₃H₁₆N₂O₂
• Molecular Weight: 232.28
• Mol File: 600709-74-8.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-[1-(4-hydroxy)butyl]indole-2-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[1-(4-hydroxy)butyl]indole-2-carboxamide(600709-74-8)
• EPA Substance Registry System: N-[1-(4-hydroxy)butyl]indole-2-carboxamide(600709-74-8)

Safety Data

• Hazardous Substances Data: 600709-74-8(Hazardous Substances Data)

Upstream product

• 1477-50-5 Indole-2-carboxylic acid 
• 13325-10-5 4-Aminobutanol 

Downstream Products

• 1022081-57-7 C₃₁H₂₈N₂O₂S 

Relevant articles and documents

2-phenylcyclopropyl methylamine derivative, and preparation method and application thereof

The invention discloses a 2-phenylcyclopropyl methylamine derivative, and a preparation method and application thereof. The 2-phenylcyclopropyl methylamine derivative provided by the invention has a structure as shown in the following formula I, has affinity activity to a dopamine receptor and/or a 5-hydroxytryptamine receptor, and can be used for treating mental diseases.

Novel Bivalent Ligands Based on the Sumanirole Pharmacophore Reveal Dopamine D2 Receptor (D2R) Biased Agonism

The development of bivalent ligands has attracted interest as a way to potentially improve the selectivity and/or affinity for a specific receptor subtype. The ability to bind two distinct receptor binding sites simultaneously can allow the selective activation of specific G-protein dependent or β-arrestin-mediated cascade pathways. Herein, we developed an extended SAR study using sumanirole (1) as the primary pharmacophore. We found that substitutions in the N-1- and/or N-5-positions, physiochemical properties of those substituents, and secondary aromatic pharmacophores can enhance agonist efficacy for the cAMP inhibition mediated by Gi/o-proteins, while reducing or suppressing potency and efficacy toward β-arrestin recruitment. Compound 19 was identified as a new lead for its selective D2 G-protein biased agonism with an EC50 in the subnanomolar range. Structure-activity correlations were observed between substitutions in positions N-1 and/or N-5 of 1 and the capacity of the new bivalent compounds to selectively activate G-proteins versus β-arrestin recruitment in D2R-BRET functional assays.

Novel Aryl Piperazine Derivatives With Medical Utility

This invention provides novel aryl piperazine derivatives having medical utility, in particular as modulators of dopamine and serotonin receptors, preferably the D3, D2-like and 5-HT2 receptor subtypes, and in particular u